JCR Pharmaceuticals Co Ltd 2020 IR
The report outlines JCR Pharmaceuticals' business activities and sustainability initiatives for FY2019, marking the final year of its 'HIYAKU' midterm plan and the launch of its new 'REVOLUTION' plan for FY2020-FY2022. The company achieved record net sales of 24,781 million yen, driven by strong product sales of GROWJECT and TEMCELL HS Inj. Key milestones included the launch of Darbepoetin Alfa BS Inj. [JCR] and the acquisition of ArmaGen, Inc. to secure its lead in blood-brain barrier penetration technology. JCR also advanced its sustainability efforts, focusing on rare diseases, environmental conservation, and human resource management.
Company: JCR Pharmaceuticals Co Ltd
Sector: Health Care
Country: Japan
Year: 2020
Type: IR
Pages: 68
JCR Pharmaceuticals Co Ltd
Report
The report outlines JCR Pharmaceuticals' business activities and sustainability initiatives for FY2019, marking the final year of its 'HIYAKU' midterm plan and the launch of its new 'REVOLUTION' plan for FY2020-FY2022. The company achieved record net sales of 24,781 million yen, driven by strong product sales of GROWJECT and TEMCELL HS Inj. Key milestones included the launch of Darbepoetin Alfa BS Inj. [JCR] and the acquisition of ArmaGen, Inc. to secure its lead in blood-brain barrier penetration technology. JCR also advanced its sustainability efforts, focusing on rare diseases, environmental conservation, and human resource management.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women on Board
Women in Management
Employees